

Title: Ivabradine reduces baseline and stress-induced increase of heart rate and blood pressure and modulates neuroendocrine stress response in rats depending on stressor intensity

Running title: Ivabradine modulates stress response

Create date: 2018-11-03

<i>Name</i>	<i>Affiliations</i>
Katarina Ondicova	1. Institute of Physiology, Faculty of Medicine, Bratislava, Slovakia
Noemi Hegedusova	1. Institute of Physiology, Faculty of Medicine, Bratislava, Slovakia
Miroslav Tibensky	1. Institute of Physiology, Faculty of Medicine, Bratislava, Slovakia
Boris Mravec	1. Institute of Physiology, Faculty of Medicine, Bratislava, Slovakia

Corresponding author: Boris Mravec <boris.mravec@fmed.uniba.sk>

Abstract

Ivabradine, a selective inhibitor of the sinoatrial pacemaker, is used in clinical practice to reduce heart rate. However, its potential effect on the neuroendocrine stress response has not been investigated. Therefore, we determined the effect of administering ivabradine to rats on cardiovascular parameters and plasma levels of epinephrine, norepinephrine, and corticosterone. Ivabradine was administered intraperitoneally 30 min before exposing animals to either handling, restraint, or immobilization stress. Heart rate and blood pressure were monitored telemetrically. Blood samples were collected before, during, and after stressor exposure to determine the extent of the neuroendocrine stress response as reflected by plasma epinephrine, norepinephrine, and corticosterone levels. In animals pretreated with ivabradine, significantly lower values of heart rate and blood pressure were found during both the baseline period and during exposure to stressors, as well as during the rest period following stressor exposure. Ivabradine also significantly reduced handling-induced epinephrine and norepinephrine release into the bloodstream. However, ivabradine significantly potentiated restraint- and immobilization-induced increases of plasma epinephrine levels, whereas stress-induced changes in plasma norepinephrine and corticosterone levels were ambiguous. Our data shows that ivabradine significantly reduces blood pressure in rats during both baseline and stressful conditions, and also affects the neuroendocrine stress response. These findings show that viscerosensory signaling from the cardiovascular system may significantly modulate the neuroendocrine stress response.

Keywords: blood pressure; corticosterone; epinephrine; heart rate; ivabradine; norepinephrine

Changelog

Author's Response to Reviewers

Reviewer #1:

We would like to thank Reviewer #1 for his/her positive comments and suggestions. We followed the recommendations and hope that you find the revised version of the manuscript satisfactory.

1a. Does the ivabradine cross the blood-brain barrier? Please, justify it with scientific reports, since it is a very important issue related to the question raised.

We added into the Introduction of revised version of the manuscript the information that ivabradine does not cross blood-brain barrier (Young et al. 2014). As mentioned in the Discussion, this is an important fact that excludes the direct effect of ivabradine on brain structures involved in regulation of neuroendocrine stress response.

1b. Which is the action mechanism of ivabradine? Specifically, does it act via any mechanism that might affect the hormonal responses evaluated?

Ivabradine represents a highly selective inhibitor of sinoatrial funny current that plays a crucial role in depolarization of cardiomyocytes. There are no data related to ivabradine direct effect on cells of endocrine glands. Moreover, there are no data that ivabradine affects other organs or tissues (exception represents retina).

1c. Cardiovascular system is still responsive (see comments below). Is not possible that these changes might activate viscerosensory nerves?

We are fully agree. We suggest that the transmission of viscerosensory signals from the heart is involved in altered neuroendocrine responses to ivabradine administration. We suggest that ivabradine-related reduction of heart rate attenuate transmission of signals from heart's mechanoreceptors, as mentioned in the Discussion.

2. Introduction: The mechanism (i.e., action mechanism) by which ivabradine evokes sinoatrial pacemaker activity blockade should be included. Additionally, the advantage of this drug to answer the study's question should be also presented.

Information related to the effect of ivabradine were added into the Introduction. Rational basis related to advantages of this drug to answer the study question are now described in the Introduction in more clear way.

3. Page 5, "fear-inducing stress": The designation of the aversive stimuli as "STRESSORS" is more appropriate than "fear-inducing stress", since no behavioral analysis were performed to evaluate the "fear" component of the aversive stimuli.

Manuscript was significantly revised – now is focused on the role of visceral signalization on neuroendocrine stress response. Only in the Discussion, potential role of visceral signalization in shaping emotion is shortly mentioned. "Fear-inducing stress" and word "fear" was changed to "stress" throughout the manuscript.

4. RESULTS: The pharmacological treatment evokes a massive decrease in cardiovascular parameters (especially the HR) before the stress session. In this sense, evaluation of cardiovascular responses to stress via analysis of absolute values of MAP and HR can evoke misinterpretations. For instance, authors mention throughout the manuscript that MAP and HR responses were decreased. However, it seems that changes (i.e., values immediately before versus during stress) are the same (or even higher in case of MAP response to handling). My suggestion is that changes (i.e., difference in values during stress vs before stress) rather the absolute values is analyzed. It seems that it will change significantly the data interpretation.

We are thankful for this note. Differences between pre-stress value (-5 min interval) and values in stress intervals were calculated and marked in graphs by "+". Related information were added into the Results – last paragraph of the section "The effect of ivabradine on heart rate and mean arterial pressure during handling, restraint stress, or immobilization"

5. RESULTS: How do the authors explain the opposite effect of ivabradine in EPI (increase) and NOR (decrease) responses to restraint and immobilization? It is poorly explored in the discussion. Text explaining above-mentioned differences were added into the Discussion.

6. DISCUSSION, page 9, third paragraph: It was demonstrated for several stressors, including the restraint, a sympathetic and parasympathetic coactivation (rather than an opposite change in sympathetic and parasympathetic) (for review, see Crestani, Front Physiol. 7:251, 2016). Please review.

During extensive revision of the manuscript, text related to the role of sympathetic and parasympathetic nerves in regulation of heart rate was excluded.

7. Discussion, page 10: The authors discuss the differences in neuroendocrine responses to the different stressors in terms of the physical activity (struggle) observed in restraint and immobilization, which is absent in handling. However, in the Methods session the authors mentioned that these stressors were chosen because of the different intensities of stress evoked by them.

Description of stressors “severity” was unified throughout the manuscript according to description in the Methods.

8. Discussion, page 11, line 4: This discussion needs to be revised. The idea of "feed-forward" indicates a response that is evoked without any sensorial information, which is exactly the opposite of reflex (responses evoked by a sensory stimulus). The idea of “conditioning” is not appropriately used as well, since it presumes the pairing of two events. It is not clear the two events that are paired during an acute session of stress to evoke the physiological responses.

Text of the Discussion was extensively modified. The idea of "feed-forward" was completely excluded. We hope that specification of conditioned and unconditioned factors make our hypothesis clearer.

Reviewer #2:

We would like to thank Reviewer #2 for his/her positive comments and suggestions. We followed the recommendations and hope that you find the revised version of the manuscript satisfactory.

1. The main problem of the manuscript arises from the author’s effort to focus on fear and emotions. No behavioral tests were used to confirm the presence of fear or anxiety and their level. I suggest to focus on stressor intensity and exclude all parts related to fear.

Parts related to fear were excluded throughout the manuscript. Now we are focusing on the effect of viscerosensitive signaling on neuroendocrine stress response.

2. There is no clear hypothesis. The aim of the study should be formulated as concrete hypotheses, not only “investigation of the effect”.

The last paragraph of the Introduction was modified. We hope that the hypothesis is now more clearly articulated.

3. The description of Results is given in insufficient detail. Results on ANOVA should be written more detailed. Both factors (treatment, time) and interactions between factors should be stated. Degrees of freedom along with a significance level ($F=...$, $p=$) for all significant main effects as well as interaction between factors need to be added. The same should be done in case of Student t-test results (both t-values and p-values should be stated).

Above-mentioned statistical description was added in the section Results.

4. The discussion is written too extensively and needs to be re-written in a more concise form. The first three paragraphs should be deleted. I strongly suggest starting the Discussion with the

summary of main findings obtained.

The Discussion was extensively modified and shortened, the first paragraphs were excluded.

5. The authors observed opposite effects of restraint and immobilization on epinephrine and norepinephrine levels. Can you please discuss this finding?

These findings are now discussed in more details in the Discussion.

6. Can you please give more information how the area under the curve was calculated? Was it calculated as an AUC with respect to ground or with respect to increase?

AUC was calculated with respect to ground.

7. I suggest replacing the collocation “fear-inducing stressors” only by “stressors” as no behavioral test was conducted to assess fear or anxiety. The same applies also for “conditions with mild fear”. Handling is a condition of mild stress intensity.

Collocation “fear-inducing stressors” was replaced by word “stressors” throughout the manuscript.

References

Young GT, Emery EC, Mooney ER, Tsantoulas C, McNaughton PA. 2014. Inflammatory and neuropathic pain are rapidly suppressed by peripheral block of hyperpolarisation-activated cyclic nucleotide-gated ion channels. *Pain* 155: 1708-1719.

Response to reviews:

response to reviews file - [download](#)

Supplementary files

manuscript track changes - [download](#)

1 **Ivabradine reduces baseline and stress-induced increase of heart rate and blood pressure**
2 **and modulates neuroendocrine stress response in rats depending on stressor intensity**

3
4
5 **Katarina Ondicova^{1#}, Noemi Hegedusova^{1#}, Miroslav Tibensky^{2,3}, Boris Mravec^{2,3}**

6
7
8 *¹Institute of Pathophysiology, Faculty of Medicine, Comenius University in Bratislava, Slovakia*

9 *²Institute of Physiology, Faculty of Medicine, Comenius University in Bratislava, Slovakia*

10 *³Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of*
11 *Sciences, Bratislava, Slovakia*

12
13
14
15 # both authors participated equally

16
17 ***Correspondence to:***

18 Prof. Boris Mravec, M.D., PhD.

19 Institute of Physiology

20 Faculty of Medicine, Comenius University in Bratislava

21 Sasinkova 2, 813 72 Bratislava, Slovakia

22 Tel: +421 2 59357527

23 Fax: +421 2 59357601

24 E-mail: boris.mravec@fmed.uniba.sk

25
26 Running title: **Ivabradine reduces blood pressure and modulates neuroendocrine stress**
27 **response**

29 **Abstract**

30 Ivabradine, a selective inhibitor of the sinoatrial pacemaker, is used in clinical practice to
31 reduce heart rate. However, its potential effect on the neuroendocrine stress response has not
32 been investigated. Therefore, we determined the effect of administering ivabradine to rats on
33 cardiovascular parameters and plasma levels of epinephrine, norepinephrine, and corticosterone.
34 Ivabradine was administered intraperitoneally 30 min before exposing animals to either handling,
35 restraint, or immobilization stress. Heart rate and blood pressure were monitored telemetrically.
36 Blood samples were collected before, during, and after stressor exposure to determine the extent
37 of the neuroendocrine stress response as reflected by plasma epinephrine, norepinephrine, and
38 corticosterone levels. In animals pretreated with ivabradine, significantly lower values of heart
39 rate and blood pressure were found during both the baseline period and during exposure to
40 stressors, as well as during the rest period following stressor exposure. Ivabradine also
41 significantly reduced handling-induced epinephrine and norepinephrine release into the
42 bloodstream. However, ivabradine significantly potentiated restraint- and immobilization-induced
43 increases of plasma epinephrine levels, whereas stress-induced changes in plasma norepinephrine
44 and corticosterone levels were ambiguous. Our data shows that ivabradine significantly reduces
45 blood pressure in rats during both baseline and stressful conditions, and also affects the
46 neuroendocrine stress response. These findings show that viscerosensory signaling from the
47 cardiovascular system may significantly modulate the neuroendocrine stress response.

48

49 **Key words:** blood pressure; corticosterone; epinephrine; heart rate; ivabradine; norepinephrine

50

51 **Introduction**

52 The stress response is a highly orchestrated reaction of an organism to external or internal
53 factors (stressors) that disrupt homeostasis [32]. Crucial components of the neuroendocrine stress
54 response include the sympathoadrenal system (SAS) and hypothalamo-pituitary-adrenocortical
55 axis (HPA) [4]. Whereas a balanced neuroendocrine stress response is essential for survival,
56 altered activation of the SAS or HPA axis, in either magnitude or duration, might have
57 detrimental effects on the organism [11, 20, 21]. Therefore, the activity of the SAS and HPA axis
58 are modulated by several mechanisms, including feedback signaling from visceral organs [12].

59 While the effect of increased SAS activity on cardiovascular system function has been well
60 described [9], the role of signals transmitted from the cardiovascular system to the brain in
61 modulating SAS and HPA axis activity during stressful situations remains unclear. Increased
62 heart rate, accompanied by more frequent activation of heart mechanoreceptors, represents a
63 typical response to psychosocial and physical stressors [19]. While these changes in heart rate
64 detected by cardiac mechanoreceptors are known to be transmitted to the brain [24], it is unclear
65 whether or not these signals affect the neuroendocrine stress response.

66 Several methodological issues make it difficult to investigate the role of viscerosensory
67 signaling from the heart in modulating the neuroendocrine stress response. Firstly, it is difficult to
68 selectively manipulate heart rate without affecting the regulatory effects of the neuroendocrine
69 stress response on peripheral tissues and organs via the SAS and HPA axis. For example, cardiac
70 denervation in patients after heart transplantation leads to damage of both viscerosensory and
71 autonomic motor nerve fibers [25, 26]. Additionally, pharmacological approaches exert a low
72 degree of selectivity. For example, β -blockers, besides causing a reduction of heart rate, also
73 affect the activity of other visceral organs and tissues, which induces various changes to the
74 internal environment [10] that are subsequently signaled to the brainstem and other structures
75 involved in regulating stress-related neuroendocrine stress responses. Fortunately, ivabradine, a
76 highly selective inhibitor of the sinoatrial funny current, was developed in the 1990's. Ivabradine
77 selectively blocks f-channels on cardiac pacemaker cells that determine spontaneous electrical
78 pacemaker activity in the sinoatrial node. This reduced current inhibits slow diastolic
79 depolarization, thereby reducing heart rate [1, 7, 30]. It was also found that ivabradine may affect
80 blood flow in some vascular beds [8]. However, there are no data showing that ivabradine has a
81 significant effect on the activity of endocrine glands or other visceral tissues and organs. In

82 addition, ivabradine does not cross the blood-brain barrier [33] and therefore cannot directly
83 affect brain functions. Based on these data, we propose that this drug provides an opportunity to
84 investigate the effect of selective inhibition of heart rate on various physiological functions,
85 including activity of the SAS and HPA axis.

86 Base on the above-mentioned facts, using ivabradine, a drug that selectively reduces heart
87 rate without affecting the activity of other visceral organs and tissues in the body [6, 23], we
88 investigated the role of signaling that accompanies a stress-induced rise in heart rate on the extent
89 of the neuroendocrine stress response. In our study, rats pretreated by ivabradine were exposed to
90 handling, restraint stress, or immobilization while plasma epinephrine (EPI), norepinephrine
91 (NE), and corticosterone levels were assayed. Furthermore, to confirm the efficacy of ivabradine-
92 induced attenuation of stress-induced increases in heart rate, cardiovascular parameters were
93 monitored telemetrically.

94

95 **Materials and Methods**

96 **Animals**

97 Male Sprague-Dawley rats weighing 250 – 300 g (Charles River Laboratories International
98 Inc., Germany) were housed three per cage under controlled conditions (12/12 h light/dark cycle
99 with lights on at 6:00 AM, temperature $22 \pm 1^\circ\text{C}$), with food and water provided *ad libitum*.
100 Experiments were performed between 08:00 - 12:00 a.m. The experiments were carried out in
101 accordance with the Council Directive 2010/63EU of the European Parliament and the Council of
102 22nd September 2010 on the protection of animals used for scientific purposes.

103

104 **Experimental design**

105 We performed two series of experiments (Fig. 1). In the first experiment, the effects of IVA
106 pretreatment on cardiovascular function in rats exposed to fear-inducing stressors were analyzed
107 using telemetric devices. In the second experiment, the effects of ivabradine on neuroendocrine
108 stress responses in rats was determined by measuring plasma EPI, NE, and corticosterone levels
109 using immunoassay methods.

110

111

112

113 **Exposure of animals to stressors**

114 Three stressors; handling, restraint stress, and immobilization, each differing in their extent of
115 activation of the neuroendocrine stress response were used and were performed as previously
116 described [3, 15]. Handling, a mild psychological stressor, was performed by gentle manipulation
117 of the animals. To do this, each animal was removed from the cage and gently manipulated using
118 both hands. Because animals accommodate to this stressor relatively fast, rats in our experiments
119 were only handled for 5 min. Restraint, a stronger stressor with predominant psychological and
120 less intense physical components, was performed by placing the animal into a plastic tube that
121 restricted its movements. Immobilization, a strong stressor with both physical and psychological
122 components, was performed by taping of all four limbs to metal holders attached to an
123 immobilization board. As a result of this the animal was not able to move, breathing was
124 hampered, and acral parts of limbs were ischemic [16, 17].

125 126 **Attenuation of stress-induced increase of heart rate by ivabradine pretreatment**

127 Ivabradine (Procoralan 5 mg, Les Laboratoires Servier, Neuillysur-Seine, France) was
128 dissolved in saline and injected intraperitoneally (5 mg/kg bw) in rats (IVA group). The vehicle
129 treated rats were given an intraperitoneal injection of saline (SAL group). Ivabradine or saline in
130 a volume of 2 mL/kg were administered 30 min before exposure of animals to stressor. The dose
131 of ivabradine was chosen based on our pilot experiment in which we have found that this dose is
132 sufficient to prevent stress-induced increase of heart rate.

133 134 **Monitoring of cardiovascular system activity**

135 In the first experiment, rats were randomly divided into IVA and SAL groups and exposed to
136 5 min handling (n = 4), 60 min restraint (n = 4), or 60 min immobilization (n = 4). Heart rate and
137 mean arterial pressure were recorded by telemetric devices with Millar catheters (model
138 TRM54P, Telemetry Research, Auckland, New Zealand) implanted into the abdominal aorta
139 seven days prior to the exposure of rats to the stressors (for details of implantation of telemetry
140 devices see [22]). Briefly, animals were anesthetized with an intramuscular administration of a
141 ketamine (Narkamon 5%; 1.2 mL/kg) and xylazine (Rometa 2%; 0.4 mL/kg) mixture. The tip of
142 the Millar catheter was placed into the aorta above the bifurcation of its abdominal part. The
143 transmitter was then placed into the abdominal cavity and attached to the peritoneum using

144 sutures. The abdomen was then closed in two layers with interrupted sutures. To avoid post-
145 operational infection, intramuscular injection of antibiotics (penicillin) was given immediately
146 after implantation. After surgery, rats were housed separately with free access to tap water and
147 pelleted food.

148 The recording of cardiovascular parameters started 60 min prior to the exposure to stressors.
149 This interval represented baseline values analogical to the control interval used during blood
150 sampling in the second experiment (see below). These cardiovascular parameters were
151 continuously recorded during the entire exposure to stressors and also for the next 120 min
152 (handling) or 60 min (restraint, immobilization) as an analogy to the rest interval during blood
153 sampling (see below).

154

155 **Determination of neuroendocrine stress response**

156 In the second experiment, rats were randomly divided into IVA and SAL groups and exposed
157 to handling (n = 17), restraint (n = 18), or immobilization (n = 13) stress, respectively. Blood
158 samples (0.4 mL) were collected at defined time intervals via a cannula implanted into the jugular
159 vein one day prior to the exposure of animals to stressors. The cannulation of the jugular vein
160 allows for repeated blood sampling without inducing any stress effects and was performed as
161 previously described [31]. Briefly, animals were anesthetized with a mixture of ketamine-
162 xylazine as described above. The rats were then fixed in a supine position to an acrylic surgery
163 platform. The area of incision (15 mm long) was on the right shoulder close to the base of the
164 neck. To reach the jugular vein it was necessary to separate the surrounding muscle and
165 membranous tissue. The exposed jugular vein was cut with spring-scissors on the upper surface
166 and a polyethylene tube (silicon tubing, PE 50; Becton-Dickinson, Parsippany, NJ) filled with
167 heparinized saline (300 IU/mL) was carefully placed into the right jugular vein. About 0.1 mL of
168 the heparinized saline was then infused through the catheter and a slow withdrawal of blood was
169 attempted to confirm correct cannulation procedure. The cannula was tied to the vein with rostral
170 and caudal ligatures to avoid occluding the cannula. Following this, the rat was removed from the
171 platform and we made a small incision in the center of the rat's nape with a trochar. The end of
172 the cannula was then advanced into the trochar and exteriorized at the other end of the ventral
173 incision, and was then attached with medical thread. After cannulation, the rats were housed
174 individually. Exposure to stressors and blood sampling started on the next day after the overnight

175 recovery. The duration of the 1 day recovery was selected according to our previous experiments
176 and findings showing that jugular vein cannulation does not increase baseline corticosterone
177 levels 1 day after cannulation and does not alter subsequent stress responses in animals exposed
178 to stressors 1 or more days after the surgical procedure [18].

179 Approximately 30 min before of the start of blood sampling, the free end of the jugular
180 catheter was connected with a longer cannula to allow unstressed blood collection. Before
181 ivabradine injection, the first blood samples (control samples) were collected from unstressed
182 rats. Afterwards, the blood samples were collected via cannula at the time points of 0 and 5 min
183 during handling and at 15, 30, 60, and 120 min after handling (rest phase). During restraint and
184 immobilization, blood samples were collected at the 5, 15, 30, and 60 min time points during
185 exposure, as well as 60 min after the end of exposure to stressor (rest phase). To replace the lost
186 volume of blood (0.4 mL) each rat was administered an equal volume of heparinized saline (50
187 IU/mL) by cannula.

188

189 **Biochemical analysis of plasma**

190 Immediately after collecting blood samples, Eppendorf vials containing the collected blood
191 were placed on ice and centrifuged at 3000g for 15 min at 4°C to separate plasma. Plasma
192 samples were stored at -70°C until analyzed. Plasma catecholamine concentrations were
193 determined by a commercially available enzyme immunoassay kit (2-CAT (A-N) Research
194 ELISA, LDN, Nordhorn, Germany). The minimum detection limit for catecholamines in this
195 ELISA kit is 8.1 pg/mL for EPI and 5.4 pg/mL for NE (depending on sample volume). Plasma
196 corticosterone concentration was determined by a commercially available radioimmunoassay kit
197 (Corticosterone rat/mouse RIA kit, DRG Diagnostic, Germany). The minimum detection limit for
198 corticosterone in these RIA kits is 7.7 ng/mL.

199

200 **Statistical analysis**

201 Statistical analysis was performed using GraphPad Prism 5 program (GraphPad Software,
202 San Diego CA, USA). Statistical differences between the groups were determined by two-way
203 analyses of variance (ANOVA) with repeated measures followed by post hoc, pair wise
204 comparisons using Bonferroni's correction and an unpaired Student's t-test. Data are presented as
205 mean \pm SEM and represent the mean for 4 rats in experiments monitoring cardiovascular activity

206 and 8 – 10 rats in experiments determining the neuroendocrine stress response. The p value of <
207 0.05 was taken as indicative of statistical significance. The area under the curve (AUC) was
208 calculated based on the concentration \times time as a measure of the magnitude of the response. The
209 AUC represents an integrated value of the total amount of hormone released during the 5 min of
210 handling, 60 min of restraint stress, or 60 min of immobilization.

211

212 **Results**

213 **The effect of ivabradine on heart rate and mean arterial pressure during handling,** 214 **restraint stress, or immobilization**

215 Continual telemetric recording demonstrated that heart rate and mean arterial pressure
216 increased only slightly after intraperitoneal injection of saline (-30 min interval) compared to pre-
217 injection period (-35 min interval). Furthermore, before exposure to stressors (handling, restrain
218 or immobilization; -5 min interval) values of these cardiovascular parameters slightly lower or
219 even reached control values in animals injected by saline (Fig. 2A, 3A, 4A). In contrast, injection
220 of ivabradine 30 min prior to exposure to the stressor significantly reduced values of heart rate
221 and mean arterial pressure during the time intervals prior to the exposure of animals to stressors
222 (-15 min and -5 min; Fig. 2A, 3A, 4A).

223 Whereas exposure of saline-treated rats to stressors induced increase of heart rate and blood
224 pressure, animals injected with ivabradine showed significantly reduced values of heart rate and
225 mean arterial pressure during exposure to stressors, as well as during following rest period
226 (Handling HR: $F_{1,60}=6496.45$, $p < 0.001$, MAP: $F_{1,60}=721.53$, $p < 0.001$, Fig. 2A; Restrain HR:
227 $F_{1,54}=1477.63$, $p < 0.001$, Restrain MAP: $F_{1,54}=257.58$, $p < 0.001$; Fig. 3A; Immobilization HR:
228 $F_{1,60}=434.72$, $p < 0.001$, Immobilization MAP: $F_{1,54}=298.72$, $p < 0.001$; Fig. 4A).

229 When comparing the -5 min, pre-stress interval with the subsequent stress and post-stress rest
230 intervals, exposure to stressors induces a significant increase of HR and MAP in both saline and
231 ivabradine pretreated rats. This increase was more prominent in saline treated animals than those
232 injected with ivabradine. In handled rats this increase was found at the beginning of the handling
233 procedure, whereas by the end of handling, HR values did not differ from the pre-stress -5 min
234 interval (Fig. 2A). In rats exposed to restraint, increased values of the observed cardiovascular
235 parameters were found in several stress intervals (Fig. 3A), whereas in immobilized animals HR
236 and MAP values were increased during the entire period of immobilization (Fig. 4A).

237
238 **The effect of ivabradine on plasma catecholamines and corticosterone levels during**
239 **handling, restraint stress, or immobilization**

240 In rats exposed to handling, ivabradine pretreatment significantly decreased the total amount
241 of EPI and NE released during the 5 min handling period compared to the SAL group (EPI AUC:
242 $t_{16}=2.668$, $p < 0.05$, NE AUC: $t_{16}=5.217$, $p < 0.001$; Fig. 2B, C). On the other hand, ivabradine
243 pretreatment significantly exaggerated restraint- and immobilization-induced increases of plasma
244 EPI (Restraining EPI: $F_{1,96}=70.62$, $p < 0.001$, Fig. 3B; Immobilization EPI: $F_{1,66}=13.94$, $p < 0.001$,
245 Fig. 4B). Also, the total amount of EPI released during the 60 min restraint stress was
246 significantly higher in the IVA group compared to saline treated animals ($t_{16}=9.010$, $p < 0.001$;
247 Fig. 3B), as well as during the 60 min immobilization ($t_{11}=2.452$, $p < 0.05$; Fig. 4B). Similar to
248 handling, the total amount of released NE was significantly decreased in ivabradine-pretreated
249 rats compared to the SAL group during restraint stress ($t_{16}=2.172$, $p < 0.05$; Fig. 3C). In
250 immobilized rats, the total amount of released NE increased only slightly in rats pretreated by
251 ivabradine ($t_{16} = 1.488$, $p = 0.1488$, SAL: 119 ± 7 ng/mL/min vs. IVA: 106 ± 5 ng/mL/min; Fig.
252 4C). However, stress-induced increases in plasma corticosterone levels did not differ between the
253 IVA and SAL groups during exposure to the stressors (Fig. 2D, 3D, 4D).

254
255 **Discussion**

256 In our experiments, we have confirmed that ivabradine pretreatment significantly reduces
257 heart rate during unstressed conditions. However, contrary to the generally accepted assumption
258 that ivabradine does not affect blood pressure, we have shown that ivabradine administration
259 even in dose of 5 mg/kg bw also significantly reduced baseline blood pressure in rats. Moreover,
260 we found that ivabradine also attenuated stress-induced increases in heart rate and blood pressure.
261 In rats exposed to handling (a mild stressor), ivabradine administration significantly reduced
262 stressor-induced activation of SAS as shown by the reduced levels of EPI and NE in ivabradine
263 treated rats compared to saline injected ones. However, handling-induced activation of the HPA
264 axis, as determined by plasma corticosterone levels, was not affected by ivabradine. On the
265 contrary, ivabradine significantly potentiated restraint- and immobilization-induced increases of
266 plasma EPI levels whereas plasma NE and corticosterone levels exhibited ambiguous changes.

267 To our knowledge, there is only one study in humans investigating the effect of IVA on
268 plasma EPI and NE levels in healthy volunteers at basal conditions, as well as during tilt and
269 physical activity. They found out that ivabradine administration was associated with decreased
270 levels of heart rate and mean arterial pressure together with increased levels of EPI and NE
271 during exercises with sympathetic stimulation [13].

272 We hypothesize that the mechanisms responsible for reduced activation of SAS in rats
273 pretreated with ivabradine and exposed to a mild stressor (handling) are related to mechanisms of
274 learning by conditioning (for review see [27]). Exposure of an organism to stressors usually leads
275 to an increase in heart rate. Because activation of the neuroendocrine stress response and
276 increases in heart rate are frequently coupled, it is possible that this response develops via
277 conditioning. This conditioned response has the neuroendocrine stress response as the
278 unconditioned “factor” and increases in heart rate as conditioned “factor”. In this way, an
279 increase in heart rate is able to potentiate the neuroendocrine stress response by itself. The
280 reduction of heart rate by ivabradine also reduces the effectiveness of this conditioned response
281 and therefore may be responsible for the attenuated activity of SAS detected in handled rats
282 pretreated by ivabradine.

283 In contrast to handling, plasma EPI was increased in rats pretreated by ivabradine and
284 exposed to an intermediate stressor such as restraint stress, or a strong stressor such as
285 immobilization. We hypothesize that this is because restraint stress and immobilization represent
286 stressors that are accompanied by physical activity when animals try to escape from the restraint
287 cylinder or immobilization board, as compared to handling, which does not. This physical
288 activity may be accompanied by mild hypoxia in muscles that represents a potent stimulus for the
289 adrenal medulla, whereas sympathetic nerves releasing NE are not significantly stimulated [34].

290 In addition, we hypothesize that the ivabradine-induced reduction of heart rate in animals
291 exposed to intermediate (restraint) or intensive (immobilization) stressors is associated with
292 insufficient peripheral responses to released catecholamines into the bloodstream. For example,
293 the ivabradine-induced decrease in heart rate and blood pressure may consequently lead to
294 reduced perfusion of organs and muscles. This insufficient peripheral response to excessive
295 catecholamine release provokes additional stimulation of SAS and subsequent EPI release as
296 documented by the increased plasma EPI in ivabradine-injected rats exposed to restraint or

297 immobilization. Published data indicate that activation of baroreflex may play a pivotal role in
298 this compensatory response [5].

299 Ivabradine administration did not significantly affect stress-induced increases in plasma
300 corticosterone levels. Therefore, we suggest that afferent signaling from the cardiovascular
301 system plays a more important role in the regulation of SAS activity than the HPA axis.
302 Furthermore, these data suggest that HPA axis activity is mainly under the influence of the
303 forebrain structures activated predominantly by psychological stressors [14, 35].

304 Our findings of an attenuated neuroendocrine stress response as a consequence of reduced
305 heart rate during exposure to a mild stressor supports the assumption that while stress related
306 processes in the brain, including emotions, drive changes in the activity of visceral organs,
307 activation of visceral organs may in turn shape neuroendocrine stress response [2]. Because
308 ivabradine does not cross blood-brain barrier [33], its central effect on neuroendocrine stress
309 response may be excluded. Based on our data, we suggest that the heart is activated during stress
310 response by central commands originating in the brain, but the heart itself also modulates
311 neuroendocrine and emotional responses in the brain, as proposed the James-Lange theory of
312 emotions.

313 Transmission of signals from the heart to the brain is altered in patients who have received a
314 heart transplant. However, published data indicate that the stress response is not affected in these
315 patients [28]. This discrepancy between our findings and the above-mentioned data might be
316 related to several factors. In our experiments, we selectively prevented the stress-induced
317 increase in heart rate, while in patients with a transplanted heart, a mild stressor (Stroop test)
318 induces a slight increase in heart rate and blood pressure that may lead to activation of several
319 receptors in the cardiovascular system (e.g. mechanoreceptors in the heart, baroreceptors). In
320 addition, re-innervation occurs in a transplanted heart. Moreover, these patients are treated by
321 several drugs also affecting the heart itself. All of these factors may affect transmission of signals
322 from the transplanted heart to the brain, consequently affecting the stress response and may
323 explain the discrepancies between published data and our findings.

324 To our knowledge, this is the first study investigating the effect of attenuating stress-induced
325 heart activity by ivabradine during the neuroendocrine stress response in laboratory animals
326 exposed to different stressors. We have shown that attenuation of the stress-induced increase in
327 heart rate during conditions of mild stress reduces the response of the SAS. These data indicate

328 that afferent signals from the heart play a significant role in modulating the neuroendocrine stress
329 response, which may highlight the importance of visceral signals in modulating emotions, as
330 originally proposed by the James-Lange theory. Therefore, psychological approaches to reducing
331 the stress-induced rise in heart rate may be of importance in neurotic individuals with an
332 exaggerated response to stressors [29]. In addition, pharmacological attenuation of heart rate
333 during stressful conditions may represent a protective strategy useful in preventing the adverse
334 effects of exaggerated SAS activation, particularly in patients with cardiovascular diseases.

335

336 **Acknowledgements**

337 This research was supported by the VEGA grant (1/0300/15) and European Regional
338 Development Fund Research and Development Grant (ITMS 26240120015). We wish to thank
339 Dr. Ken Goldstein of ScienceDocs (www.sciencedocs.com) for the editing of this paper.

340

341 **Conflict of interests**

342 The authors declare that they have no conflicts of interest.

343

344 **References**

- 345
- 346 1. Bois P, Bescond J, Renaudon B, Lenfant J (1996) Mode of action of bradycardic agent, S
347 16257, on ionic currents of rabbit sinoatrial node cells. *Br J Pharmacol* 118:1051-1057
 - 348 2. Critchley HD, Harrison NA (2013) Visceral influences on brain and behavior. *Neuron* 77:624-
349 638
 - 350 3. Day HE, Nebel S, Sasse S, Campeau S (2005) Inhibition of the central extended amygdala by
351 loud noise and restraint stress. *Eur J Neurosci* 21:441-454
 - 352 4. Delahunt JW, Mellsop G (1987) Hormone changes in stress. *Stress Med* 3:123-134
 - 353 5. Dias da Silva VJ, Tobaldini E, Rocchetti M, Wu MA, Malfatto G, Montano N, Zaza A (2015)
354 Modulation of sympathetic activity and heart rate variability by ivabradine. *Cardiovasc*
355 *Res* 108:31-38
 - 356 6. DiFrancesco D (2006) Funny channels in the control of cardiac rhythm and mode of action of
357 selective blockers. *Pharmacol Res* 53:399-406
 - 358 7. DiFrancesco D, Camm JA (2004) Heart rate lowering by specific and selective I(f) current
359 inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. *Drugs*
360 64:1757-1765
 - 361 8. Gardiner SM, Kemp PA, March JE, Bennett T (1995) Acute and chronic cardiac and regional
362 haemodynamic effects of the novel bradycardic agent, S16257, in conscious rats. *Br J*
363 *Pharmacol* 115:579-586
 - 364 9. Goldstein DS. (1995) *Stress, Catecholamines, and Cardiovascular Disease*. Oxford, New York:
365 Oxford University Press, Inc.
 - 366 10. Guglin M (2013) Heart rate reduction in heart failure: ivabradine or beta blockers? *Heart Fail*
367 *Rev* 18:517-528
 - 368 11. Chrousos GP (2009) Stress and disorders of the stress system. *Nature Reviews Endocrinology*
369 5:374-381
 - 370 12. Jänig W. (2006) *The integrative action of the autonomic nervous system. Neurobiology of*
371 *homeostasis*. Cambridge: Cambridge University Press.
 - 372 13. Joannides R, Moore N, Iacob M, Compagnon P, Lerebours G, Menard JF, Thuillez C (2006)
373 Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol
374 on systemic and cardiac haemodynamics at rest and during exercise. *Br J Clin Pharmacol*
375 61:127-137
 - 376 14. Keller-Wood M (2015) Hypothalamic-Pituitary--Adrenal Axis-Feedback Control.
377 *Comprehensive Physiology* 5:1161-1182
 - 378 15. Kvetnansky R, Mikulaj L (1970) Adrenal and urinary catecholamines in rats during
379 adaptation to repeated immobilization stress. *Endocrinology* 87:738-743
 - 380 16. Kvetnansky R, Silbergeld S, Weise VK, Kopin IJ (1971) Effects of restraint on rat
381 adrenomedullary response to 2-deoxy-D-glucose. *Psychopharmacologia* 20:22-31
 - 382 17. Kvetnansky R, Sun CL, Lake CR, Thoa N, Torda T, Kopin IJ (1978) Effect of handling and
383 forced immobilization on rat plasma levels of epinephrine, norepinephrine, and
384 dopamine-beta-hydroxylase. *Endocrinology* 103:1868-1874
 - 385 18. Ling S, Jamali F (2003) Effect of cannulation surgery and restraint stress on the plasma
386 corticosterone concentration in the rat: application of an improved corticosterone HPLC
387 assay. *J Pharm Pharm Sci* 6:246-251
 - 388 19. Lipp MN, Anderson DE (1999) Cardiovascular reactivity to simulated social stress. *Stress*
389 *Med* 15:249-257

- 390 20. Masini CV, Nyhuis TJ, Sasse SK, Day HE, Campeau S (2011) Effects of voluntary wheel
391 running on heart rate, body temperature, and locomotor activity in response to acute and
392 repeated stressor exposures in rats. *Stress* 14:324-334
- 393 21. McEwen BS, Gianaros PJ (2010) Central role of the brain in stress and adaptation: links to
394 socioeconomic status, health, and disease. *Ann N Y Acad Sci* 1186:190-222
- 395 22. Muntzel MS, Al-Naimi OA, Barclay A, Ajasin D (2012) Cafeteria diet increases fat mass and
396 chronically elevates lumbar sympathetic nerve activity in rats. *Hypertension* 60:1498-
397 1502
- 398 23. Nawarskas JJ, Bowman BN, Anderson JR (2015) Ivabradine: A Unique and Intriguing
399 Medication for Treating Cardiovascular Disease. *Cardiol Rev* 23:201-211
- 400 24. Peyronnet R, Nerbonne JM, Kohl P (2016) Cardiac Mechano-Gated Ion Channels and
401 Arrhythmias. *Circ Res* 118:311-329
- 402 25. Pozza RD, Kleinmann A, Bechtold S, Fuchs A, Netz H (2006) Reinnervation after heart
403 transplantation in children: results of short-time heart rate variability testing. *Pediatr*
404 *Transplant* 10:429-433
- 405 26. Raczak G, La Rovere MT, Mortara A, Assandri J, Prpa A, Pinna GD, Maestri R, D'Armini
406 AM, Viganò M, Cobelli F (1999) Arterial baroreflex modulation of heart rate in patients
407 early after heart transplantation: lack of parasympathetic reinnervation. *J Heart Lung*
408 *Transplant* 18:399-406
- 409 27. Ramsay DS, Woods SC (2016) Physiological Regulation: How It Really Works. *Cell Metab*
410 24:361-364
- 411 28. Salmon P, Stanford SC, Mikhail G, Zielinski S, Pepper JR (2001) Hemodynamic and
412 emotional responses to a psychological stressor after cardiac transplantation. *Psychosom*
413 *Med* 63:289-299
- 414 29. Schneider TR, Rench TA, Lyons JB, Riffle RR (2012) The influence of neuroticism,
415 extraversion and openness on stress responses. *Stress Health* 28:102-110
- 416 30. Thollon C, Cambarrat C, Vian J, Prost JF, Peglion JL, Vilaine JP (1994) Electrophysiological
417 effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac
418 preparations: comparison with UL-FS 49. *Br J Pharmacol* 112:37-42
- 419 31. Thirivikraman KV, Huot RL, Plotsky PM (2002) Jugular vein catheterization for repeated
420 blood sampling in the unrestrained conscious rat. *Brain Research Brain Research*
421 *Protocols* 10:84-94
- 422 32. Ulrich-Lai YM, Herman JP (2009) Neural regulation of endocrine and autonomic stress
423 responses. *Nat Rev Neurosci* 10:397-409
- 424 33. Young GT, Emery EC, Mooney ER, Tsantoulas C, McNaughton PA (2014) Inflammatory
425 and neuropathic pain are rapidly suppressed by peripheral block of hyperpolarisation-
426 activated cyclic nucleotide-gated ion channels. *Pain* 155:1708-1719
- 427 34. Young JB, Rosa RM, Landsberg L (1984) Dissociation of sympathetic nervous system and
428 adrenal medullary responses. *Am J Physiol* 247:E35-40
- 429 35. Ziegler DR, Herman JP (2002) Neurocircuitry of stress integration: anatomical pathways
430 regulating the hypothalamo-pituitary-adrenocortical axis of the rat. *Integr Comp Biol*
431 42:541-551

432

433

434 **Legends to figures**

435

436

437 **Figure 1.** Schematic illustration of the experimental design.

438

439 **Figure 2.** The effect of saline (SAL; ○) or ivabradine (IVA; ●) pretreatment on heart rate and
440 mean arterial pressure (A), plasma epinephrine (B), norepinephrine (C), and corticosterone (D)
441 levels in rats exposed to handling (grey areas). Areas under the curve (AUC) were measured from
442 0 to 5 min of handling for the plasma catecholamines or corticosterone concentrations. Each
443 value is the mean ± SEM (n = 4 for cardiovascular parameters; n = 8 – 9 for hormones).
444 Statistical significance compared to saline pretreated group: **p* < 0.05; ***p* < 0.01; ****p* < 0.001;
445 differences between corresponding pre-stress interval (-5 min) and following intervals: ++*p* <
446 0.01; +++*p* < 0.001.

447

448 **Figure 3.** The effect of saline (SAL; ○) or ivabradine (IVA; ●) pretreatment on heart rate and
449 mean arterial pressure (A), plasma epinephrine (B), norepinephrine (C), and corticosterone (D)
450 levels in rats exposed to restraint stress (grey areas). Areas under the curve (AUC) were
451 measured from 0 to 60 min of restraint stress for plasma catecholamines and corticosterone
452 concentrations. Each value is the mean ± SEM (n = 4 for cardiovascular parameters; n = 8 – 10
453 for hormones). Statistical significance compared to saline pretreated group: **p* < 0.05; ***p* <
454 0.01; ****p* < 0.001; differences between corresponding pre-stress interval (-5 min) and following
455 intervals: +*p* < 0.05; ++*p* < 0.01; +++*p* < 0.001.

456

457 **Figure 4.** The effect of saline (SAL; ○) or ivabradine (IVA; ●) pretreatment on heart rate and
458 mean arterial pressure (A), plasma epinephrine (B), norepinephrine (C), and corticosterone (D)
459 levels in rats exposed to immobilization (grey areas). Areas under the curve (AUC) were
460 measured from 0 to 60 min of immobilization for plasma catecholamines and corticosterone
461 concentrations. Each value is the mean ± SEM (n = 4 for cardiovascular parameters; n = 6 – 7 for
462 hormones). Statistical significance compared to the saline pretreated group: **p* < 0.05; ***p* <
463 0.01; ****p* < 0.001; differences between corresponding pre-stress interval (-5 min) and following
464 intervals +*p* < 0.05; ++*p* < 0.01; +++*p* < 0.001.

Fig. 1 [Download full resolution image](#)




Fig. 2 [Download full resolution image](#)




Fig. 3 [Download full resolution image](#)




Fig. 4 [Download full resolution image](#)

